

Richard Choo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7155685/publications.pdf>

Version: 2024-02-01

50
papers

1,454
citations

361045

20
h-index

315357

38
g-index

50
all docs

50
docs citations

50
times ranked

2183
citing authors

#	ARTICLE	IF	CITATIONS
1	Surgery Versus Radiotherapy for Clinically-localized Prostate Cancer: A Systematic Review and Meta-analysis. <i>European Urology</i> , 2016, 70, 21-30.	0.9	222
2	Second malignancies after radiotherapy for prostate cancer: systematic review and meta-analysis. <i>BMJ</i> , The, 2016, 352, i851.	3.0	180
3	Neuroendocrine Differentiation in Prostate Cancer: A Mechanism of Radioresistance and Treatment Failure. <i>Frontiers in Oncology</i> , 2015, 5, 90.	1.3	116
4	Long-term outcome of postorchietomy surveillance for Stage I testicular seminoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 61, 736-740.	0.4	83
5	Individualized planning target volumes for intrafraction motion during hypofractionated intensity-modulated radiotherapy boost for prostate cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 62, 418-425.	0.4	77
6	Positive resection margin and/or pathologic T3 adenocarcinoma of prostate with undetectable postoperative prostate-specific antigen after radical prostatectomy: to irradiate or not?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2002, 52, 674-680.	0.4	63
7	(IN)-efficacy of salvage radiotherapy for rising PSA or clinically isolated local recurrence after radical prostatectomy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2002, 53, 269-276.	0.4	58
8	Identification of Site-specific Recurrence Following Primary Radiation Therapy for Prostate Cancer Using C-11 Choline Positron Emission Tomography/Computed Tomography: A Nomogram for Predicting Extrapelvic Disease. <i>European Urology</i> , 2017, 71, 340-348.	0.9	51
9	Randomized, Double-Blinded, Placebo-Controlled, Trial of Risedronate for the Prevention of Bone Mineral Density Loss in Nonmetastatic Prostate Cancer Patients Receiving Radiation Therapy Plus Androgen Deprivation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 85, 1239-1245.	0.4	48
10	Efficacy of Salvage Radiotherapy Plus 2-Year Androgen Suppression for Postradical Prostatectomy Patients With PSA Relapse. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 75, 983-989.	0.4	36
11	Patterns of Recurrence After Postprostatectomy Fossa Radiation Therapy Identified by C-11 Choline Positron Emission Tomography/Computed Tomography. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 526-535.	0.4	35
12	Prospective Assessment of Gastrointestinal and Genitourinary Toxicity of Salvage Radiotherapy for Patients With Prostate-Specific Antigen Relapse or Local Recurrence After Radical Prostatectomy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 72, 792-798.	0.4	32
13	Recommendations for CTV margins in radiotherapy planning for non melanoma skin cancer. <i>Radiotherapy and Oncology</i> , 2012, 104, 263-266.	0.3	31
14	Low dose rate prostate brachytherapy. <i>Translational Andrology and Urology</i> , 2018, 7, 341-356.	0.6	30
15	Outcomes in a Multi-institutional Cohort of Patients Treated With Intraoperative Radiation Therapy for Advanced or Recurrent Renal Cell Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 88, 618-623.	0.4	28
16	Establishment of practice standards in nomenclature and prescription to enable construction of software and databases for knowledge-based practice review. <i>Practical Radiation Oncology</i> , 2016, 6, e117-e126.	1.1	26
17	Prospective survey of sexual function among patients with clinically localized prostate cancer referred for definitive radiotherapy and the impact of radiotherapy on sexual function. <i>Supportive Care in Cancer</i> , 2010, 18, 715-722.	1.0	23
18	How are hemoglobin levels affected by androgen deprivation in non-metastatic prostate cancer patients?. <i>Canadian Journal of Urology</i> , 2005, 12, 2547-52.	0.0	23

#	ARTICLE	IF	CITATIONS
19	Salvage Radiotherapy for Patients with PSA Relapse Following Radical Prostatectomy: Issues and Challenges. <i>Cancer Research and Treatment</i> , 2010, 42, 1.	1.3	22
20	Effect of combined treatment with salvage radiotherapy plus androgen suppression on quality of life in patients with recurrent prostate cancer after radical prostatectomy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 65, 78-83.	0.4	20
21	Long-term outcomes of radiotherapy for stage II testicular seminoma—the Mayo Clinic experience. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 1832-1838.	0.8	20
22	What is the microscopic tumor extent beyond clinically delineated gross tumor boundary in nonmelanoma skin cancers?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 62, 1096-1099.	0.4	19
23	Survey of radiation oncologists: practice patterns of the management of stage I seminoma of testis in Canada and a selected group in the United States. <i>Canadian Journal of Urology</i> , 2002, 9, 1479-85.	0.0	18
24	Brachytherapy in the Management of Prostate Cancer. <i>Surgical Oncology Clinics of North America</i> , 2017, 26, 491-513.	0.6	17
25	Limited efficacy of salvage radiotherapy for biopsy confirmed or clinically palpable local recurrence of prostate carcinoma after surgery. <i>Radiotherapy and Oncology</i> , 2005, 74, 163-167.	0.3	16
26	Prospective Study Evaluating Postoperative Radiotherapy Plus 2-Year Androgen Suppression for Post-Radical Prostatectomy Patients With Pathologic T3 Disease and/or Positive Surgical Margins. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 75, 407-412.	0.4	16
27	IMPT versus VMAT for Pelvic Nodal Irradiation in Prostate Cancer: A Dosimetric Comparison. <i>International Journal of Particle Therapy</i> , 2019, 5, 11-23.	0.9	16
28	Analysis of Gastrointestinal and Genitourinary Morbidity of Postoperative Radiotherapy for Pathologic T3 Disease or Positive Surgical Margins After Radical Prostatectomy Using National Cancer Institute Expanded Common Toxicity Criteria. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 72, 989-995.	0.4	15
29	Excellent long-term disease control with modern radiotherapy techniques for stage I testicular seminoma—the Mayo Clinic experience. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 24.e1-24.e6.	0.8	12
30	Comparison of Multimodal Therapies and Outcomes Among Patients With High-Risk Prostate Cancer With Adverse Clinicopathologic Features. <i>JAMA Network Open</i> , 2021, 4, e2115312.	2.8	12
31	Prospective Evaluation of Quality of Life in Prostate Cancer Patients Receiving Combined Treatment of Postoperative Radiotherapy Plus Androgen Suppression for PT3 or Positive Resection Margin after Radical Prostatectomy. <i>European Urology</i> , 2007, 52, 1645-1652.	0.9	11
32	Late gastrointestinal morbidity in patients with stage II testicular seminoma treated with radiotherapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 496-500.	0.8	9
33	Single-fraction Stereotactic Body Radiation Therapy versus Conventionally Fractionated Radiation Therapy for the Treatment of Prostate Cancer Bone Metastases. <i>Advances in Radiation Oncology</i> , 2019, 4, 314-322.	0.6	9
34	Is there any benefit in adding postoperative adjuvant concurrent radiotherapy and chemotherapy for penile cancer with regional lymph node metastasis?. <i>Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology</i> , 2020, 72, 474-481.	3.9	9
35	Elective pelvic nodal irradiation with a simultaneous hypofractionated integrated prostate boost for localized high risk prostate cancer: Long term results from a prospective clinical trial. <i>Radiotherapy and Oncology</i> , 2021, 163, 21-31.	0.3	7
36	Comparing bowel and urinary domains of patient-reported quality of life at the end of and 3 months post radiotherapy between intensity-modulated radiotherapy and proton beam therapy for clinically localized prostate cancer. <i>Cancer Medicine</i> , 2020, 9, 7925-7934.	1.3	6

#	ARTICLE	IF	CITATIONS
37	Proton Therapy for Stage IIA-B Seminoma: A New Standard of Care for Treating Retroperitoneal Nodes. <i>International Journal of Particle Therapy</i> , 2018, 5, 50-57.	0.9	6
38	Two different perspectives in the management of pT3 and/or margin-positive prostate cancer after radical prostatectomy. <i>BJU International</i> , 2006, 98, 773-776.	1.3	5
39	Can radiotherapy be a viable salvage treatment option for the relapsed seminoma confined to the infra-diaphragm region recurring after primary chemotherapy for bulky stage II seminoma?. <i>Canadian Urological Association Journal</i> , 2013, 4, 137.	0.3	5
40	Proton Therapy of Prostate and Pelvic Lymph Nodes for High Risk Prostate Cancer: Acute Toxicity. <i>International Journal of Particle Therapy</i> , 2021, 8, 41-50.	0.9	5
41	Long-term results of a study using individualized planning target volumes for hypofractionated intensity-modulated radiotherapy boost for prostate cancer. <i>Radiation Oncology</i> , 2015, 10, 95.	1.2	4
42	Assessing concordance between patient-reported and investigator-reported CTCAE after proton beam therapy for prostate cancer. <i>Clinical and Translational Radiation Oncology</i> , 2021, 31, 34-41.	0.9	4
43	Approaching automated applicator digitization from a new angle: Using sagittal images to improve deep learning accuracy and robustness in high-dose-rate prostate brachytherapy. <i>Brachytherapy</i> , 2022, 21, 520-531.	0.2	4
44	Predictors of Locoregional Recurrence and Delineation of Adjuvant Radiation Therapy Fields for Patients With Upper Tract Urothelial Carcinoma Receiving Nephroureterectomy. <i>Practical Radiation Oncology</i> , 2021, 11, e468-e476.	1.1	2
45	Increased utilization of external beam radiotherapy relative to cystectomy for localized, muscle-invasive bladder cancer: a SEER analysis. <i>Bladder</i> , 2018, 5, e34.	0.6	2
46	Outcomes and Profiles of Older Patients Receiving Definitive Radiation Therapy for Muscle-Invasive Bladder Cancer at a Tertiary Medical Center. <i>Practical Radiation Oncology</i> , 2020, 10, e378-e387.	1.1	1
47	The impact of genetic mutations on response to radium-223 treatment for castration-resistant prostate cancer with bone metastases.. <i>Journal of Clinical Oncology</i> , 2020, 38, e17587-e17587.	0.8	0
48	Acute patient-reported toxicities after proton therapy or intensity-modulated radiotherapy for prostate cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 305-305.	0.8	0
49	Can radiotherapy salvage isolated local recurrence following radical prostatectomy?. <i>Canadian Journal of Urology</i> , 1997, 4, 395-399.	0.0	0
50	A phase II trial of hypofractionated radiation therapy over five treatments for prostate cancer with high-risk features after radical prostatectomy: MC1754.. <i>Journal of Clinical Oncology</i> , 2022, 40, 248-248.	0.8	0